Prostate Enucleation With Intravesical Botox Injections in Treating Benign Prostatic Hyperplasia and Bladder Overactivity : A Randomized Controlled Trial

The aim of this study is to evaluate the effect of intravesical Botox injections on lower urinary tract symptoms (LUTS) when administered during Bipolar prostate enucleation surgery in patients with bladder outlet obstruction (BOO) and overactive bladder symptoms (OAB).

Start Date01 Jan 2025

Sponsor / Collaborator

Menoufia University

NCT05393921 / Not yet recruitingPhase 4IIT

The Clinical Efficacy of Intravesical Botox Injections When Combined With HoLEP Surgery in Patients With Benign Prostatic Hyperplasia and Overactive Bladder

Benign prostatic hyperplasia (BPH) is the most common benign neoplasm in men. Almost 90% of men in their 70s report lower urinary tract symptoms related to BPH. These symptoms carry a significant negative impact on the patients' quality of life.
Despite the wide availability of surgical offerings to relieve bladder outlet obstruction such as transurethral resection of the prostate (TURP), Holmium Laser Enucleation of the Prostate (HoLEP), and prostatectomy, many patients still suffer from persistent LUTS after undergoing these. A study describing postoperative outcomes following HoLEP revealed that patients with severe lower urinary tract symptoms, storage-positive sub-score, and high maximum urinary flow rate before the surgery were affected by a rebound of mainly storage symptoms 6-8 weeks after HoLEP and prolonged recovery from LUTS with 7.4% of them presenting for persistent urge complaints.
Optimizing the management approach for these patients has been limited by lack of high level evidence-based recommendations and expert consensus. Intravesical botox injections are well-established therapeutic options for several urinary disorders. The current practice offers intravesical botox injections to patients who suffer from persistent urinary symptoms few months after their BPH procedure. This study aims to evaluate if giving botox injections at the time of the HoLEP surgery would yield a better outcome than performing the two procedures separately at different times (few months apart).
The concomitant use of botox injection during bladder de-obstructing procedures has been previously studied in TURP and have showed a significant reduction of incontinence episodes and OAB symptoms in the group that were treated with botox injections after 36 weeks post TURP. This data may suggest promising potential of this intervention in managing persistent OAB symptoms in patients with BOO. However, the efficacy of combining HoLEP and bladder Botox injections has not been systematically studied and evaluated.
The aim of this study is to evaluate the effect of intravesical Botox injections on lower urinary tract symptoms (LUTS) when administered during HoLEP surgery in patients with bladder outlet obstruction (BOO) and overactive bladder symptoms (OAB). The investigators are interested in comparing the postoperative outcome in terms of recovery and symptom relief in patients who performed HoLEP surgery with bladder Botox injections versus those who performed HoLEP surgery only at 2 weeks,1 month, 3 months, and 6 months postoperatively.
The investigators hypothesize that administering bladder botox injections during HoLEP surgery is a combination treatment that will result in faster and more potent symptom relief compared to patients who received only a HoLEP surgery for their obstructive and irritative symptoms.

Start Date30 Nov 2024

Sponsor / Collaborator-

NCT06293300 / Not yet recruitingPhase 2IIT

Understanding and Treating TBI Associated Photophobia With Botulinum Toxin Type A and Its Impact on Visual Function

The purpose of this research is to understand and treat Traumatic Brain Injury (TBI) associated photophobia (light sensitivity) and its impact on visual function.

Start Date01 Aug 2024

Sponsor / Collaborator

University of Miami

[+1]

100 Clinical Results associated with Onabotulinumtoxin A

100 Translational Medicine associated with Onabotulinumtoxin A

100 Patents (Medical) associated with Onabotulinumtoxin A

2,224

Literatures (Medical) associated with Onabotulinumtoxin A

01 May 2024·American journal of otolaryngology

Use of botox for sialorrhea and dysphagia in the neonatal population

Article

Author: Haykal, Nadine ; McCoy, Jennifer L ; Tobey, Allison B J ; Lu, Nathan

INTRODUCTION:

Botox is frequently used for sialorrhea in patients with compromised airways and those with etiologies causing difficulty with secretion management (i.e. strokes, neurologic disorders, etc.). There are no published studies regarding the use of botulinum toxin (BoNT) in the neonate population. We aim to discuss our experience and safety of BoNT use in the neonate population in regards to alleviating secretion management and airway protection.

METHODS:

Retrospective review of neonates admitted to the neonatal intensive care unit (NICU) ≤12 months of age who received BoNT injection to submandibular (SMG) and parotid (PG) glands for sialorrhea/dysphagia. BoNT was administered under ultrasound (u/s) guidance by interventional radiology.

RESULTS:

6 children were examined. 2 (33 %) were male. Avg NICU stay was 87.5 ± 33.1 days. 2 underwent surgical airway intervention prior to injection. Mean age at initial BoNT was 1.5 ± 0.7 months. Avg weight at injection was 4 ± 1.1 kg. Each PG and SMG were injected in 5/6 cases. Bilateral SMG were unidentified on u/s in 1 case and thus not injected. Dose range injected per gland was 5-15u. 100 % required tube feeds, 50 % with tubes distal to stomach (NJT/NDT). 83 % were completely NPO prior to injection and there was no noted clinical improvement in oral skills post injection. All had noted desats/apneas prior to injection and 83 % had reported decreased events post injection. 50 % had reported decrease O2 requirements and frequent suctioning 2wks after injection, however 2 (33 %) required surgical airway intervention after injection (trach, SGP/MDO). 4/6 (67 %) trialed medical therapy, anticholinergics being the most common. 50 % underwent 2nd injection (age = 6.5 ± 0.3 months) avg. 4.7 ± 0.7mo after 1st injection, and the same 3pts underwent 3rd injection (age = 12.5 ± 2.4 months) avg. 6.1 ± 2.5mo after 2nd injection. 1 pt. had a total 6 injections. There were no injection related complications.

CONCLUSION:

BoNT injection is a safe, non-invasive alterative for management of sialorrhea in neonates. Further extensive study needs to be performed to identify the optimal dose per gland in this population.

01 Mar 2024·Journal of plastic, reconstructive & aesthetic surgery : JPRAS

Ocular-oral synkinesis caused by partial injury of the zygomatic and buccal branches of the facial nerve after mid-face trauma

Article

Author: Jun, Dongkeun ; Kim, Jin ; Park, Il-Seok

BACKGROUND:

Facial nerve paralysis induced by acute traumatic facial nerve injuries limited to the zygomatic and buccal branches shows unique complications, such as strong co-contractions of the lower facial muscles around the lips during voluntary blinking (ocular-oral synkinesis). We investigated the characteristics of facial complications after facial nerve injury in the mid-face area and reported the treatment results.

METHODS:

A total of 21 patients with facial nerve injuries to the zygomatic and/or buccal branches were evaluated for the degree of facial synkinesis and mouth asymmetry. Patients with mild-to-moderate symptoms were treated using physical rehabilitation therapy combined with botulinum toxin (Botox) injection, and patients with severe or uncontrolled symptoms were treated using surgical therapy.

RESULTS:

Initial/final mean synkinesis scores and mouth asymmetry degrees were 2.17/1.75 and 0.85/0.66 in the physical therapy group and 3.11/0.78 and 2.41/-0.31 in the surgery group, respectively. Physical therapy with Botox injection alone did not show significant improvements in synkinetic symptoms of the patients with mild-to-moderate synkinesis (p > 0.05), whereas surgical therapy resulted in significant improvements in synkinesis and mouth asymmetry (p < 0.05).

CONCLUSIONS:

Surgical treatment is an effective adjustment procedure for the management of facial complications in patients with severe or uncontrolled synkinesis after facial nerve injury to the mid-face area.

01 Feb 2024·Journal of cosmetic dermatology

Botox resistance and COVID‐19 vaccines: Is type B Botox a viable solution?

Letter

Author: Mehta, Devina ; Wildman, Horatio

217

News (Medical) associated with Onabotulinumtoxin A

20 Jun 2024

·www.fiercepharma.com

No sweat for dermatology specialist Botanix as hyperhidrosis gel Sofdra gains FDA approval

Hyperhidrosis is the third largest dermatology market behind acne and atopic dermatitis, according to Botanix. Everybody sweats, but for the 10 million people in the U.S. living with primary axillary hyperhidrosis, sweating can take on a whole new meaning. The condition is hallmarked by sweating beyond the level necessary to regulate body temperature. Primary axillary hyperhidrosis specifically refers to the underarms and has major effects on quality of life, potentially impacting patients' work productivity, social interactions and emotional well-being. It’s been years since a new treatment hit the market in this condition. With an FDA approval in hand, Botanix hopes its topical gel Sofdra can change the game. The drug won FDA approval to treat primary axillary hyperhidrosis in patients ages 9 and older. It’s the first and only new chemical entity cleared for the condition, Botanix said in a press release. Current treatment options include AbbVie’s Botox injections and different formulations of glycopyrrolate. Many of the marketed therapies aren’t as targeted as Sofdra so they can dry out other fluids, such as tears, saliva and even cause urinary retention, Botanix’s founder and board executive director, Matt Callahan, said in a recent interview. In two phase 3 studies that enrolled a total of 701 patients, the gel helped patients achieve clinically and statistically meaningful improvements from baseline levels in the Gravimetric Sweat Production scale and the Hyperhidrosis Disease Severity Measure-Axillary score, according to the company's release. Reaching the roughly 10 million U.S. patients with primary axillary hyperhidrosis will require a unique commercial approach for Botanix, especially considering that fewer than half of patients have an official diagnosis, according to the company. Bearing in mind the social challenges the condition presents, many patients may be actively searching online to find a treatment, as opposed to visiting the dermatologist’s office, Callahan said. Botanix will reach these patients through a “very strong digital approach” that includes a telemedicine component. “This is kind of one of those areas where people don't like to talk about it much and dermatologists don't seem to know much about it,” Callahan explained. “So we're trying to solve that problem with a telemedicine approach to provide a better service and a better fulfillment option to these patients.” Still, the large patient population makes for a “massive opportunity” for Botanix, the executive said. Sofrda is the Australia-based company’s first commercial product. It will come with a price tag “on par” with other treatments on the market, but the key difference, Callahan said. Prescription wipe Qbrexza has an average retail price of $771, according to GoodRx. Considering 90% of those with hyperhidrosis also suffer from excessive sweating in other areas of the body, there is “lots of future potential” from a label expansion perspective, Callahan noted. Callahan says Botanix is something of a “hidden gem” on the Australian Stock Exchange, but the drugmaker plans to become “the next big dermatology company in the U.S.," he added. Its U.S. operations are based in Pennsylvania and Arizona, and the company is also working on treatments for acne and rosacea. The approval makes for a “transformative event” for the company as it transitions “from a development stage to a revenue-generating dermatology company,” CEO Howie McKibbon, M.D., added in Botanix's release. The drugmaker will roll out initial doses through an early patient experience program during this year’s third quarter. The wider launch is expected to take off during the fourth quarter.

Phase 3Drug ApprovalClinical Result

12 Jun 2024

·www.prnewswire.com

REVDOC'S DISRUPTIVE TECHNOLOGY ALLOWS PROVIDERS TO OFFER SEMAGLUTIDE FOR $179

Any registered provider on the new app can offer the highly sought-after Semaglutide compound to their patients at a fraction of the cost TAMPA, Fla., June 12, 2024 /PRNewswire/ -- RevDoc is a revolutionary app that connects healthcare providers to users for doctor visits at home, the office or anywhere. Providers on RevDoc are now offering Semaglutide with B-12 starting at just $179 with no hidden costs and free shipping. The breakout drug, which has the same active ingredient as Ozempic and Wegovy, has seen a steady increase in usage as it has successfully helped users safely lose a significant amount of weight. The drug often comes with a high price tag, with many med spas offering it at $500-600 a month. RevDoc providers will offer Semaglutide for $179 for the first month and $199 ongoing for Rev+ users, including a telemedicine consultation. With just a few taps on the user-friendly RevDoc mobile app, a verified doctor will come to you —whether you're at home, the office, a hotel, dorm or via telemedicine. RevDoc offers access to over 100 healthcare services, including primary and urgent care, weight loss, men's and women's health, sports medicine, aesthetic treatments like Botox® and laser skin treatments, labs and more. As a groundbreaking first double-sided app in healthcare, RevDoc allows providers to easily sign up wherever they are. Once their background verification is complete, they have the flexibility to work for themselves and start building a practice and setting their own hours and rates. The RevDoc platform, which is free for providers, includes a complete electronic medical record, prescription management, direct pay options and the ability to order medical supplies, leveraging group rates and enabling doctors to focus on providing care, not paperwork. By reducing the administrative burden of middlemen, RevDoc makes access to house calls surprisingly cost-effective and accessible for everyone. RevDoc's founder, Anil "AK" Kottoor, is no stranger to the healthcare industry, having launched and run multiple companies in the healthcare and technology sectors, including FutureRx and MHK. With RevDoc, AK plans to further disrupt the industry by offering access to healthcare and aesthetic services at affordable prices, starting in Florida and quickly moving nationwide, with no insurance interference necessary. "It is remarkable how much you can save when you eliminate the middleman and implement technology," said AK, Founder of RevDoc. "RevDoc provides power to the patient and the medical provider by creating a two-sided marketplace that eliminates third parties and the administrative burden imposed by insurance companies. We are reimagining healthcare by providing access to the best care at the lowest cost, directly to patients." Users interested in the Semaglutide offer can download the RevDoc app to find a provider and schedule a telemedicine consultation. If they are eligible for Semaglutide, the compound will be prescribed and shipped to their home. The starting dose of 0.25 ml is recommended for the first month to ensure medication tolerance and assess for possible side effects. RevDoc does not sell private user or provider information to third parties and follows HIPAA guidelines for security and confidentiality. RevDoc is a technology company that connects consumers with healthcare providers of choice and the performance of any and all health care services is solely the activity of participating healthcare providers. ABOUT REVDOC: Founded in Tampa Bay in 2023, RevDoc brings the doctor to your doorstep. With a first-of-its-kind mobile app, access to hundreds of health and aesthetic services, from Botox® at home to urgent care in the office and skin-rejuvenating lasers in a Luxe Mobile Clinic. Wherever consumers are, RevDoc connects them with healthcare providers in their service area. No more waiting rooms. Personalized healthcare without surprise bills, rushed appointments, or battles with insurance companies. Patients can use HSA/FSA/HRA debit cards or credit cards for hassle-free payments. For more information, visit revdoc.com. For more information, please contact: Sarah Henriksen | PRESS PR + Marketing Phone: 407-233-9615 Email: [email protected] SOURCE RevDoc

08 May 2024

·www.biospace.com

QULIPTA™ (atogepant) Now Approved by Health Canada for the Preventive Treatment of Chronic Migraine in Adults

QULIPTA is now the first and only oral calcitonin gene-related peptide (CGRP) receptor antagonist (gepant) approved to prevent migraine across all frequencies, including episodic and chronic. Expanded indication provides an additional treatment option for those with chronic migraine whose frequent disabling attacks negatively impact performance of daily activities. Approval was based on a pivotal Phase 3 clinical trial that demonstrated statistically significant reduction from baseline in mean monthly migraine days. AbbVie is the only pharmaceutical company to offer three treatments across the full spectrum of migraine to help patients living with this debilitating disease. MONTRÉAL, May 8, 2024 /CNW/ - AbbVie (NYSE: ABBV) announced today that Health Canada has approved QULIPTA (atogepant) for the prevention of migraine in adults who have at least four migraine days per month.1 QULIPTA is the first and only oral, small-molecule calcitonin gene-related peptide (CGRP) receptor antagonist (gepant) approved to prevent both episodic and chronic migraine. "QULIPTA has been helping thousands of Canadians living with episodic migraine since December 2022. Now, QULIPTA offers a new option for those with the most challenging-to-treat chronic migraine," says Rami Fayed, Vice President and General Manager, AbbVie Canada. "With this approval, AbbVie is the only pharmaceutical company with three treatments across the entire migraine spectrum, including QULIPTA as a preventive treatment for both episodic and chronic migraine, BOTOX® (onabotulinumtoxinA) our foundational preventive treatment for chronic migraine, and UBRELVY® (ubrogepant), an acute treatment for migraine attacks." QULIPTA's expanded chronic migraine indication is based on the pivotal Phase 3 PROGRESS trial evaluating QULIPTA 60 mg once daily in adult patients with chronic migraine, which met its primary endpoint of statistically significant reduction of -6.9 from baseline in mean monthly migraine days compared to placebo of -5.1 across the 12-week treatment period.2 The average monthly migraine days (MMDs) for patients at baseline during the clinical trial was 19.2. "Chronic migraine is incredibly debilitating for my patients. It makes day-to-day activities often unbearable, and isolates you from friends, family, and work," says Dr Ian Finkelstein, Medical Director of the Toronto Headache & Pain Clinic. "I have observed QULIPTA's ability to alleviate the challenges posed by episodic migraine in many of my patients, resulting in improved functionality, impressive response rates, and sustained efficacy. I'm excited to see Health Canada's approval of QULIPTA for chronic migraine and to be able to offer another treatment option to patients to help them successfully prevent their migraines." QULIPTA blocks CGRP through a once-daily dose and is available in three strengths for the preventive treatment of episodic migraine – 10 mg, 30 mg and 60 mg. Only the 60 mg dose of QULIPTA is indicated for the preventive treatment of chronic migraine. The overall safety pro QULIPTA is consistent with the episodic migraine patient population, with the most common adverse events including nausea, constipation, diarrhoea, and fatigue.1 "Bringing new migraine-specific medications to Canadians living with migraine is critical as so many have yet to find the relief they seek," says Wendy Gerhart, Executive Director of Migraine Canada. "Chronic migraine is a constant struggle for too many. We are pleased to see the approval of QULIPTA for this indication providing another safe and effective option and are confident it will have a positive impact on our community." About Migraine Migraine is a complex neurological disease with recurrent attacks that lasts 4-72 hours. It can be defined by symptoms such as moderate to severe pain intensity, nausea, vomiting, photophobia and phonophobia.3 An estimated 2.7 million Canadians are reported diagnosed with migraine, however the number of people living with migraine is much higher.4 Episodic migraine is characterized as having less than 15 headache days per month, while 15 headache days or more per month, is considered chronic.5 About QULIPTA (atogepant) QULIPTA (atogepant) is the first and only oral, small-molecule calcitonin gene-related peptide (CGRP) receptor antagonist (gepant) specifically developed for the preventive treatment of episodic and chronic migraine. QULIPTA is an orally administered, small-molecule, selective calcitonin gene-related peptide (CGRP) receptor antagonist that blocks the binding of the CGRP to its receptor. CGRP is a neuropeptide that may play a role in migraine pathophysiology.1 For important safety information, please consult the QULIPTA Product Monograph. About AbbVie in Neuroscience At AbbVie, our commitment to people around the world living with neurological and psychiatric disorders is unwavering. With more than three decades of experience in neuroscience, we are providing meaningful treatment options today and advancing innovation for the future. AbbVie's Neuroscience portfolio consists of approved treatments in neurological conditions, including migraine, movement disorders, and psychiatric disorders, along with a robust pipeline of transformative therapies. We have made a strong investment in research and are committed to building a deeper understanding of neurological and psychiatric disorders. Every challenge makes us more determined and drives us to discover and deliver advancements for those impacted by these conditions, their care partners, and clinicians. For more information, visit . About AbbVie AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas – immunology, oncology, neuroscience, and eye care – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at . Follow AbbVie Canada on X, Instagram, or LinkedIn. For more information on AbbVie's complete migraine portfolio, please visit SOURCE AbbVie Canada Company Codes: NYSE:ABBV

Phase 3Drug ApprovalClinical Result

100 Deals associated with Onabotulinumtoxin A

External Link

KEGG	Wiki	ATC	Drug Bank
D08957	Onabotulinumtoxin A	M03AX01	DB00083

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Masticatory Muscles, Hypertrophy Of	CN	Allergan, Inc.	03 Jun 2024
Neurogenic detrusor overactivity	US	AbbVie, Inc.	22 Aug 2022
Urinary Incontinence	US	AbbVie, Inc.	22 Aug 2022
Dysphonia	JP	GSK Plc	25 May 2018
Forehead lines	US	AbbVie, Inc.	02 Oct 2017
Bladder dysfunction	US	AbbVie, Inc.	04 Apr 2017
Lateral Canthal Lines	US	AbbVie, Inc.	11 Sep 2013
Limb spasticity	US	AbbVie, Inc.	09 Mar 2010
Equinus Deformity	JP	Allergan, Inc.	21 Jan 2009
Hyperhidrosis	JP	Allergan, Inc.	21 Jan 2009
Migraine Disorders	JP	-	21 Jan 2009
Urinary Bladder, Neurogenic	JP	Allergan, Inc.	21 Jan 2009
Urinary Bladder, Overactive	JP	Allergan, Inc.	21 Jan 2009
Cervical Dystonia, Primary	JP	GSK Plc	03 Oct 2005
Muscle Spasticity	-	Genesis Healthcare, Inc.	03 Oct 2005
Primary Axilary Hyperhidrosis	US	AbbVie, Inc.	19 Jul 2004
Strabismus	US	AbbVie, Inc.	19 Jul 2004
Blepharospasm	CN	Allergan Pharmaceuticals Ireland ULC	22 Apr 2003
Muscle Cramp	CN	Allergan Pharmaceuticals Ireland ULC	22 Apr 2003
Torticollis	JP	GSK Plc	20 Jun 2000

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Headache	Phase 3	CN	GlaxoSmithKline (China) Investment Co., Ltd.	17 Jan 2017
Headache	Phase 3	CN	Allergan Pharmaceuticals Ireland ULC	17 Jan 2017
Crow's feet	Phase 3	CN	Allergan Pharmaceuticals Ireland ULC	16 Sep 2014
Crow's feet	Phase 3	CN	GlaxoSmithKline (China) Investment Co., Ltd.	16 Sep 2014
Cerebral Palsy	Phase 3	US	Allergan Plc	12 Jul 2012
Cerebral Palsy	Phase 3	CA	Allergan Plc	12 Jul 2012
Cerebral Palsy	Phase 3	HU	Allergan Plc	12 Jul 2012
Cerebral Palsy	Phase 3	PH	Allergan Plc	12 Jul 2012
Cerebral Palsy	Phase 3	PL	Allergan Plc	12 Jul 2012
Cerebral Palsy	Phase 3	RU	Allergan Plc	12 Jul 2012

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05248867 (CTgov)	Phase 3	Glabellar frown lines	638	Placebo+AGN-151586 (Placebo)	hyzyriofkl(ouztdlhhmf) = nwlpsatsqm rpmxarqmze (jigjmidmad, mdrsqesqud - hkjlmovfzk) View more	-	24 May 2024
				AGN-151586 (AGN-151586)	hyzyriofkl(ouztdlhhmf) = rvijtanugg rpmxarqmze (jigjmidmad, fedeplykeh - prunjpsfna) View more
NCT03779841 (CTgov)	Phase 2	Atrial Fibrillation	323	Placebo (Placebo)	whzobimskp(ffnxktkcqp) = rqajmpbqrq iusxljhirs (fclwwvqnjw, lxwchrfies - brxynmaokl) View more	-	14 May 2024
				AGN-151607 (AGN-151607 (125 U))	whzobimskp(ffnxktkcqp) = ltilvunnuc iusxljhirs (fclwwvqnjw, hedalgdibu - pjhwpcpbzz) View more
NCT05248867 \| NCT05248880 (M21-508, Corporate Publications) Manual	Phase 3	Glabellar frown lines	947	TrenibotulinumtoxinE (BoNT/E)	mhpmnmtoqu(erlpubxxoj) = ywogtqrtzc jselumqrdj (rbxagyvdli ) Met	Positive	24 Oct 2023
				Placebo	-
CNS2023	Phase 2	Headache	45	Onabotulinumtoxin A	xwlkhkgijx(gqurgdfwcy) = zsmohhaoem ghhyarfefn (hpkrqyjzpu, 0 - 17) View more	-	01 Oct 2023
NCT04994535 (M21-310, Corporate Publications) Manual	Phase 3	Platysma Prominence	426	Onabotulinumtoxin A	uhoxkyveva(mghznkknyi): P-Value = <0.0001 Met View more	Positive	18 Sep 2023
				Placebo
NCT03137407 (CTgov)	Phase 2	Fasciitis, Plantar	59	Placebo (Placebo)	oebpcqasny(vqovusyltd) = jomyvjzret prqnajhikj (nzkmhsstcu, bfybzogjez - brzflmnjju) View more	-	28 Aug 2023
				Botulinum Toxins, Type A (DAXI 240 U)	pzpqrdukch(fjzkkwhgex) = khfgplyapq rzyovgojzr (pxwiypdukk, yjvbfpnebe - louhpjrfws) View more
NCT05127018 (CTgov)	Phase 1/2	Botulism	33	botulinum toxin type A+Botox (the First Injection(the Average-dose Method))	vsbfeeseyl(tfxrdrjylw) = cfcyswfzgm mmijlcsbud (owilnhrmjd, cnupvfburv - nbxpaxmvmy) View more	-	26 Apr 2023
				botulinum toxin type A+Botox (the Second Injection(the Higher-dose Method))	vsbfeeseyl(tfxrdrjylw) = jcjyurnkdp mmijlcsbud (owilnhrmjd, hxadiheeir - uytmgnbbvd) View more
AUA2023	Not Applicable	Urinary Bladder, Neurogenic	101	NLUTD patients receiving BTX-A	bhhgngjvkp(nmwrzrebyg) = wxygrezlte xghokpcgck (sttfaimhop ) View more	-	01 Apr 2023
NCT03991299 (CTgov)	Phase 1/2	Diabetes Mellitus, Noninsulin-Dependent, 2 \| Weight Loss \| Obesity	4	Botox 200 UNT Injection	sghevmjrgs(natibjznen) = cdrtgcnfjb mzfbjbunmq (xfarngwwtc, jpxemrhrms - lplklsvzfi) View more	-	28 Feb 2023
AAO2022	Not Applicable	Benign Essential Blepharospasm	-	OnabotulinumtoxinA	eykurjhztd(gplqilfvld) = lalsaewuow gfsqqdxsrp (doxvzvlkfs )	-	29 Sep 2022

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis